Roche's James Sabry inks his second AI deal in back-to-back pacts — this time partnering Genentech with Stanford spinout Genesis Therapeutics

Genentech has inked a deal with Stanford spinout Genesis Therapeutics to harness its AI power for drug development and discovery. Genesis is getting an upfront payment and milestones, but the companies are keeping the details under wraps for now. The Burlingame, CA-based biotech also stands to earn future royalties on any approved Genentech drugs that come from the deal.